Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same

Patent metadata

Field	Value
Publication number	US-11498965-B2
Application number	US-201816754431-A
Country	US
Kind code	B2
Filing date	Oct 22, 2018
Priority date	Oct 20, 2017
Publication date	Nov 15, 2022
Grant date	Nov 15, 2022

Abstract

The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

First claim

The invention claimed is:

1. An antibody or an antigen-binding fragment thereof, said antigen or antigen-binding fragment thereof comprising:
(a-1) a light chain variable domain (VL domain) comprising the amino acid sequence of SEQ ID NO: 7 or 8; and
(a-2) a heavy chain variable domain (VH domain) comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, or 21, or (b-1) a light chain variable domain (VL domain) comprising the amino acid sequence of SEQ ID NO: 15 or 16; and
(b-2) a heavy chain variable domain (VH domain) comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, or 25,
wherein the VL domain of (a-1) and (b-1) comprises complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 29, CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and CDR3 comprising the amino acid sequence of SEQ ID NO: 31; and
wherein the VH domain of (a-2) and (b-2) comprises complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 32, CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and CDR3 comprising the amino acid sequence of SEQ ID NO: 34.

2. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof specifically binds to cluster of differentiation 3 (CD3).

3. The antibody or the antigen-binding fragment thereof of claim 2 , wherein the CD3 includes human-derived CD3 and monkey-derived CD3.

4. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof specifically binds to T cells.

5. The antibody or the antigen-binding fragment thereof of claim 4 , wherein the T cells include human-derived T cells and monkey-derived T cells.

6. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody is a humanized antibody.

7. A polynucleotide that encodes the light chain variable domain (VL domain) and the heavy chain variable domain (VH domain) of the antibody or the antigen-binding fragment thereof of claim 1 .

8. An expression vector comprising the polynucleotide of claim 7 .

9. A host cell transformed with the expression vector of claim 8 .

10. A method for producing an antibody that specifically binds to CD3, comprising culturing the host cell of claim 9 .

11. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 1 .

12. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 2 .

13. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 3 .

14. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 4 .

15. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 5 .

16. A pharmaceutical composition comprising the antibody or the antigen-biding fragment thereof of claim 6 .

Assignees

• Green Cross Corp
• Mogam Inst Biomedical Res

Inventors

• Kim Ki Su
• Jeong Jun Hong
• Yoon Ae Rin
• Song Eun Jung
• Choi Hye Ji
• Lim Ok Jae
• Lee Yun Jung
• Lim Hyung Kwon
• Won Jong Wha

Classifications

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title